Opens in a new tab

Tandem Diabetes Care v Roche Diabetes Care (CFI, ORD_9062/2024, 20 February 2024)

Date20 February 2024
CourtCFI
DivisionParis (FR) Central Division - Seat
Type of actionGeneric application
Registry referenceApp_8392/2024 · ORD_9062/2024
PartiesRoche Diabetes Care GmbH

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By order of 20 February 2024 (UPC_CFI_455/2023), Paolo Catallozzi, judge-rapporteur of the Paris Central Division, hearing the action for a declaration of non-infringement of EP 2 196 231 brought on 30 November 2023 by Tandem Diabetes Care, Inc. and Tandem Diabetes Care Europe B.V. against Roche Diabetes Care GmbH, refused Roche’s request to extend the time limit for its Defence to 8 April 2024 or, in the alternative, 18 March 2024. The preliminary objection to jurisdiction lodged by Roche on 22 January 2024 does not suspend that time limit.

Question

Do a pending preliminary objection, the cost of pleadings that may prove unnecessary and the prospect of an infringement action leading to a stay (Rule 76.3) justify an extension under Rule 9.3 or a contrary decision under Rule 19.6?

Decision

No. Rule 9.3 confers a discretion to be exercised in line with proportionality, flexibility, fairness and equity (paragraphs 8 and 9), extensions are exceptional and require that compliance be objectively impossible or very difficult (paragraphs 16 and 17). Roche relied only on the possibility that its pleadings might prove useless (paragraph 18), the risk of a stay is irrelevant (paragraph 19). Rule 19.6, applicable through Rule 66, keeps the time limit for the Defence running despite the preliminary objection, unless the judge-rapporteur decides otherwise under the same requirements (paragraphs 20 to 23). The alleged need for clarity in relation to the parallel revocation action was not explained (paragraph 24).

Key points for practice

Provisions applied

Rules of Procedure
Rules 9.3, 9.4, 19.6, 23, 66, 76.3 and 333
Case law cited
ITCiCo Spain, Paris Central Division, 9 February 2024, Paris Central Division, order of 10 November 2023, UPC_CFI_255/2023

Related decisions

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Going further

Lexicon: Written procedure (UPC), Court fees and costs (UPC).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

No case number recorded in this record.

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Generic application
Outcome (Dhenne Avocats summary)
Le juge rapporteur refuse de proroger le délai du mémoire en défense de Roche dans l'action en déclaration de non-contrefaçon, l'exception préliminaire pendante ne suspendant pas ce délai.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 2 196 231
System for ambulatory drug infusion comprising a filling apparatus for flexible containers
recorded proprietor: F Hoffmann La Roche AG et Roche Diagnostics GmbH
Mentioned in the analysis (role not qualified)
Also mentioned in 9 other decision(s): Tandem Diabetes Care Europe v Roche Diabetes Care (CFI, 18 December 20 · Tandem Diabetes Care Europe v Roche Diabetes Care (CoA, 3 July 2025) · Tandem Diabetes Care Europe v Roche Diabetes Care (CoA, 5 June 2025) · Roche Diabetes Care v Tandem Diabetes Care (CFI, 9 September 2024) · Roche Diabetes Care v Tandem Diabetes Care (CFI, 26 July 2024) · Tandem Diabetes Care v Roche Diabetes Care (CFI, 27 June 2024) · Tandem Diabetes Care v Roche Diabetes Care (CFI, 10 May 2024) · Tandem Diabetes Care v Roche Diabetes Care (CFI, ORD_9060/2024, 20 Feb
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.